NASDAQ · TARS
Tarsus Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for TARS: Nov 3, 2026
Tarsus Pharmaceuticals, Inc. Common Stock is estimated to report earnings on 11/03/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.43. The reported EPS for the same quarter last year was $-0.3.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.43 | $-0.76 | $-2.01 | 4 |
| Dec 2026 | $-3.45 | $-0.14 | $-9.57 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · The Motley Fool · MarketBeat- Zacks · Oct 29, 4:35 PM EDTGilead Sciences (GILD) Q3 Earnings and Revenues Top EstimatesGilead (GILD) delivered earnings and revenue surprises of +17.51% and +6.21%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Oct 29, 3:58 AM EDTTarsus Names Neera Clase Commercial Chief To Expand XDEMVY Reach And Lead Pipeline Planning(RTTNews) – Wednesday, Tarsus Pharmaceuticals, Inc. (TARS) said it has appointed Neera Clase as Chief Commercial Officer (CCO), effective November 1, 2026.
- Zacks · Oct 28, 9:00 AM EDTHarmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings GrowthHarmony Biosciences (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 27, 9:00 AM EDTEarnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to DeclineTarsus Pharmaceuticals (TARS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- RTTNews · Sep 4, 9:16 AM EDTTarsus Pharmaceuticals Completes Alkeus Acquisition; Adds Phase 3 Stargardt Disease Program(RTTNews) – Tarsus Pharmaceuticals, Inc. (TARS), an eye care-focused biopharmaceutical company, on Friday announced the completion of its previously announced acquisition of privately held Alkeus Pharmaceuticals, Inc., expanding its pipeline with the late-stage investigational me
- The Motley Fool · Aug 13, 2:32 PM EDTTarsus (TARS) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 7, 1:04 PM EDTTarsus Pharmaceuticals Q2 Earnings Call Highlights3 Biotech Catalysts Present Major OpportunityTarsus Pharmaceuticals (NASDAQ:TARS) reported second-quarter growth in sales of its Demodex blepharitis treatment XDEMVY and announced a pending acquisition of Alkeus Pharmaceuticals, adding late-stage investigational Stargardt disease
- RTTNews · Aug 7, 11:45 AM EDTWeekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data(RTTNews) – This week's biotech roundup captured a mix of regulatory wins, restructuring action, and deal momentum driving sector sentiment. FDA and EU approvals spanned oncology, vaccines and rare disease, while layoffs and cost-saving measures underscored operational tightening
- RTTNews · Aug 6, 8:45 AM EDTTarsus Pharmaceuticals To Acquire Alkeus Pharmaceuticals(RTTNews) – Tarsus Pharmaceuticals, Inc (TARS), a biopharmaceutical company focused on eye care, has entered into a definitive agreement to acquire Alkeus Pharmaceuticals, Inc., a retinal disease-focused biotechnology company.
- Zacks · Aug 6, 8:20 AM EDTTarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue EstimatesTarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of -104.76% and +5.01%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 30, 10:00 AM EDTAgenus (AGEN) Earnings Expected to Grow: Should You Buy?Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Jul 29, 10:00 AM EDTTarsus Pharmaceuticals, Inc. (TARS) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseTarsus Pharmaceuticals (TARS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Tarsus Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.